News Quantified

CLRB – cellectar biosciences, inc. (US:NASDAQ)

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

3/10

08:40 am

clrb

Medium

Cellectar Biosciences (CLRB) was upgraded by Maxim Group from "hold" to "buy". They now have a $10.00 price target on the stock.

Cellectar (CLRB) Q4 2025 Earnings Call Transcript [Yahoo! Finance]

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates [Yahoo! Finance]

Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}